Immix Biopharma, Inc. (NASDAQ:IMMX) Sees Large Increase in Short Interest

Immix Biopharma, Inc. (NASDAQ:IMMX - Get Free Report) was the recipient of a large increase in short interest during the month of May. As of May 31st, there was short interest totalling 289,700 shares, an increase of 35.6% from the May 15th total of 213,600 shares. Based on an average daily trading volume, of 196,400 shares, the short-interest ratio is currently 1.5 days. Approximately 1.8% of the shares of the company are sold short.

Institutional Trading of Immix Biopharma

A hedge fund recently bought a new stake in Immix Biopharma stock. SBI Securities Co. Ltd. purchased a new position in Immix Biopharma, Inc. (NASDAQ:IMMX - Free Report) in the fourth quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor purchased 17,500 shares of the company's stock, valued at approximately $38,000. SBI Securities Co. Ltd. owned 0.06% of Immix Biopharma as of its most recent SEC filing. Institutional investors and hedge funds own 11.26% of the company's stock.

Wall Street Analysts Forecast Growth

Separately, HC Wainwright reiterated a "buy" rating and issued a $7.00 price objective on shares of Immix Biopharma in a research report on Wednesday, June 4th.

Immix Biopharma Price Performance

Shares of NASDAQ IMMX traded up $0.10 during trading on Wednesday, hitting $2.38. 74,473 shares of the company were exchanged, compared to its average volume of 154,947. The company has a market cap of $66.33 million, a price-to-earnings ratio of -3.39 and a beta of 0.31. Immix Biopharma has a 1 year low of $1.26 and a 1 year high of $3.00. The firm's fifty day moving average price is $2.03 and its 200 day moving average price is $1.97.

Immix Biopharma (NASDAQ:IMMX - Get Free Report) last issued its earnings results on Monday, March 24th. The company reported ($0.16) EPS for the quarter, topping the consensus estimate of ($0.25) by $0.09. On average, research analysts forecast that Immix Biopharma will post -0.87 earnings per share for the current year.

About Immix Biopharma

Immix Biopharma, Inc, a clinical-stage biopharmaceutical company, engages in developing tissue-specific therapeutics in oncology and inflammation in the United States and Australia. The company is developing IMX-110 that is in Phase 1b/2a clinical trials for the treatment of soft tissue sarcoma and solid tumors; IMX-111, a tissue-specific biologic for the treatment of colorectal cancers; and IMX-120, a tissue-specific biologic for the treatment of ulcerative colitis and severe Crohn's disease.